Dmitri Abelski to build a $10 million pharmaceutical complex

ZAO PharmaScience, a new company, was established in Belarus in December 2024. The company plans to manufacture and sell eye drops.

 

A closed joint-stock company is not required to disclose its owners under its legal structure. However, Buro discovered who is behind this company.

 

We learned that PharmaScience has four beneficiaries.

 

The first is Dmitri Abelski, the eldest son of Senator Irina Abelskaia, who also heads the Medical Commission of Lukashenko’s Property Management Department.

 

The second owner is Aleh Pazniak. He is the co-founder and deputy director of Voka, Belarus’s largest network of ophthalmology clinics. Since 2018, Dmitri Abelski has worked as an ophthalmologist at Voka.

 

ВAt PharmaScience, Pazniak also serves as director.

 

Dmitri Abelski (far left) and Aleh Pazniak (far right) at the opening of the Voka clinic in Hrodna. Source: grodnoplustv.by

 

We also found that Andrei and Valery Yaramchuk are among PharmaScience’s beneficiaries. They both work for a private pharmaceutical manufacturing company called Farmtekhnologia. Their father, Aliaksandr Yaramchuk, owns a 55.1% majority stake in Farmtekhnologia.

 

Abelski & Co. have set ambitious goals for themselves. The company plans to build its own plant to produce and sell eye drops with an annual capacity of up to 10 million packages.

 

The pharmaceutical complex will be located in the Great Stone Special Economic Zone. PharmaScience registered there as a resident on May 12, 2026. Construction of the plant is expected to be completed by 2027–2028, at which point the facility will reach its full capacity of 10 million packages per year. By that time, Abelski and his partners expect to generate 10 million Belarusian rubles in revenue (about $3.5 million) and at least 3 million rubles in net profit ($1.05 million).

 

The total cost of the project is estimated at $10 million. Financing for the construction of the plant will come from a combination of bank loans, its own funds, borrowings, and investments. In September 2025, PharmaScience had already issued bonds worth 3.5 million Belarusian rubles (about $1.2 million) to raise funds from investors. It seems the company intends to use the funds to rent space, buy equipment, refine production processes, and hire qualified specialists before starting large-scale construction.